Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction...

Area of Science:

• Pharmacology
• Analytical Chemistry
• Clinical Diagnostics

Background:

• Bevantolol is an adrenergic-receptor blocker used for cardiovascular conditions.
• Accurate quantification of bevantolol in human plasma is crucial for therapeutic drug monitoring and pharmacokinetic studies.
• Existing analytical methods may lack the specificity, sensitivity, or efficiency required for routine clinical application.

Purpose of the Study:

• To develop and fully validate a sensitive and specific analytical method for bevantolol determination in human plasma.
• To establish a reliable method for quantifying bevantolol concentrations for clinical and research purposes.
• To provide a robust analytical tool for pharmacokinetic and pharmacodynamic investigations of bevantolol.

Main Methods:

• Solid-phase extraction (SPE) using Sep-pak silica cartridges for sample preparation from 1 mL of human plasma.
• High-performance liquid chromatography (HPLC) with a reverse-phase C8 analytical column.
• Isocratic elution with a mobile phase of dibasic ammonium phosphate (50 mM, pH 5.7) and acetonitrile (75:25, v/v), detected at 220 nm.

Main Results:

• The method demonstrated high specificity across six different human plasma sources.
• Linearity was established over a concentration range of 40-1600 ng/mL with a correlation coefficient of 0.9995.
• The lower limit of quantification was determined to be 40 ng/mL with a precision of 10.9% coefficient of variation.

Conclusions:

• A fully validated, specific, and sensitive method for bevantolol determination in human plasma has been successfully developed.
• The established method is suitable for accurate quantification of bevantolol in pharmacokinetic studies and therapeutic drug monitoring.
• This analytical approach provides a valuable tool for the clinical management and research of bevantolol therapy.